Literature DB >> 19230533

Modular endoprosthetic reconstruction in malignant bone tumors: indications and limits.

Maurice Balke1, Helmut Ahrens, Arne Streitbürger, Georg Gosheger, Jendrik Hardes.   

Abstract

Modular tumor prostheses are well established today for the reconstruction of osseous defects after resection of malignant bone tumors. Almost every joint and even total bones (e.g., total femur or humerus) can be replaced with promising functional results, dramatically reducing the need for ablative procedures. Although the complication rate with the use of modern modular endoprostheses is constantly decreasing, the need for revision surgery is still significantly higher than in primary joint arthroplasty. In this review we present the modular endoprosthesis system developed in our institution, summarize the postoperative management, and discuss the indications, limits, and complications as well as the functional results.

Entities:  

Mesh:

Year:  2009        PMID: 19230533     DOI: 10.1007/978-3-540-77960-5_4

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  5 in total

Review 1.  [New surgical treatment options for bone tumors].

Authors:  D Andreou; M P Henrichs; G Gosheger; M Nottrott; A Streitbürger; J Hardes
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

Review 2.  Expanding endoprosthesis for pediatric musculoskeletal malignancy: current concepts and results.

Authors:  Lukas M Nystrom; Jose A Morcuende
Journal:  Iowa Orthop J       Date:  2010

3.  [Benign bone tumors. General principles].

Authors:  A Hillmann; T Gösling
Journal:  Unfallchirurg       Date:  2014-10       Impact factor: 1.000

Review 4.  [Diagnostics and treatment of primary bone tumors].

Authors:  T Gösling; C Probst; F Länger; H Rosenthal; U Brunnemer; C Krettek
Journal:  Chirurg       Date:  2010-07       Impact factor: 0.955

5.  MUTARS® Humero pro Femur replacement: A novel reconstructive procedure after malignant bone tumor resection of the femur in young children.

Authors:  Georg Gosheger; Martin Schulze; Marieke Mathilda de Vaal; Christoph Theil; Kristian Schneider; Andrea Laufer
Journal:  J Bone Oncol       Date:  2022-07-02       Impact factor: 4.491

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.